National Institutes of Health to Grant Exclusive License for Human Derived Monocyte Attracting Purified Peptide Products

Summary

The National Institutes of Health is considering granting an exclusive license to AlleCure Corporation to develop and commercialize a purified peptide product for treating various human infections and neoplasms. The license territory will cover the entire world, with potential limitations to specific diseases such as asthma, restenosis, hepatitis B, and cancer.